drugset / Trial / NCT01274663

A Study Of PF-05175157 In Healthy Volunteers

NCT01274663

Phase 1 Completed 63 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-05175157 in healthy volunteers.

Timeline

Start
2010-11
Primary completion
2011-05
Completion
2011-05

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-05175157 Small molecule 10 mg Oral
Subject PF-05175157 Small molecule 30 mg Oral
Subject PF-05175157 Small molecule 100 mg Oral
Subject PF-05175157 Small molecule 300 mg Oral
Subject PF-05175157 Small molecule 600 mg Oral
Subject PF-05175157 Small molecule 800 mg Oral